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Disposition
a  b  s  t  r  a  c  t
Tetrabromobisphenol  A  (TBBPA)  is  the  brominated  ﬂame  retardant  with  the  largest  produc-
tion volume  worldwide.  NTP  2-year  bioassays  found  TBBPA  dose-dependent  increases  in
uterine tumors  in  female  Wistar  Han  rats;  evidence  of reproductive  tissues  carcinogenicity
was  equivocal  in  male  rats. To  explain  this  apparent  sex-dependence,  the  disposition  and
toxicokinetic proﬁle  of  TBBPA  were  investigated  using  female  Wistar  Han  rats,  as  no  data
were available  for female  rats.  In these  studies,  the  primary  route  of elimination  follow-
ing [14C]-TBBPA  administration  (25, 250 or 1000  mg/kg)  was in  feces;  recoveries  in  72  h
were  95.7  ±  3.5%,  94.3 ±  3.6%  and 98.8 ± 2.2%,  respectively  (urine:  0.2–2%;  tissues:  <0.1).
TBBPA  was  conjugated  to mono-glucuronide  and  -sulfate  metabolites  and  eliminated  in the
bile. Plasma  toxicokinetic  parameters  for  a  250  mg/kg  dose  were  estimated  based  on  free
TBBPA, as  determined  by  UV/radiometric-HPLC  analyses.  Oral  dosing  by gavage  (250 mg/kg)
resulted in  a rapid  absorption  of compound  into  the  systemic  circulation  with  an observed
Cmax at  1.5  h  post-dose  followed  by a prolonged  terminal  phase.  TBBPA  concentrations  in
plasma  decreased  rapidly  after  an  IV dose  (25 mg/kg)  followed  by  a long  elimination  phase.
These results  indicate  low  systemic  bioavailability  (F < 0.05),  similar  to  previous  reports
using  male  rats.  Elimination  pathways  appeared  to  become  saturated  leading  to delayedFemale  rat excretion  after  a single  oral  administration  of  the  highest  dose  (1000  mg/kg);  no  such  sat-
uration  or  delay  was detected  at lower  doses.  Chronic  high  exposures  to TBBPA  may  result
in competition  for metabolism  with endogenous  substrates  in  extrahepatic  tissues  (e.g.,
SULT1E1  estrogen  sulfation)  resulting  in  endocrine  disruption.
Published by Elsevier  Ireland  Ltd.  This  is  an  open  access  article under  the  CC  BY-NC-SA1. Introduction
Tetrabromobisphenol A (TBBPA, 2,2′,6,6′-Tetrabromo-
4,4′-isopropylidene diphenol; CAS No. 79-94-7) is the
largest production volume brominated ﬂame retardant
(BFR) with >230,000 tons manufactured per year [13]. This
represents ∼60% of all worldwide demand for BFR
∗ Corresponding author at: 111 T W Alexander Drive, BG 101 Rm C202A,
Research Triangle Park, NC 27709, USA. Tel.: +1 919 541 4038;
fax:  +1 919 541 5136.
E-mail  address: gabriel.knudsen@nih.gov (G.A. Knudsen).
http://dx.doi.org/10.1016/j.toxrep.2014.03.005
2214-7500/Published by Elsevier Ireland Ltd. This is an open access article 
by-nc-sa/3.0/).license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
chemicals; TBBPA is used primarily as a reactive
(chemically-bound) ﬂame retardant in >90% of printed
circuit boards, as well as in laminates, paper, textiles,
as a plasticizer, and intermediate for the syntheses of
other  ﬂame retardants [7]. Although it has been purported
to  be sequestered in its end-use product [7], TBBPA
has been consistently detected in environmental sam-
ples  [12]. Use of TBBPA as an additive ﬂame retardant
(not chemically bound) has been reported in products
like Acrylonitrile–Butadiene–Styrene plastic casings
and this application is expected to increase as other
ﬂame retardants (e.g., high molecular weight polybromi-
nated diphenyl ethers and hexabromocyclododecanes) are
under the CC BY-NC-SA license (http://creativecommons.org/licenses/
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ithdrawn from the market [8]. This additive use increases
he  potential for its release to the environment. Recent
tudies of nursing mothers found greater than 50% of
reast  milk samples and 30% of maternal/cord serum sam-
les  contained detectable levels of TBBPA, demonstrating
idespread exposure to mothers & fetuses and potentially
o  newborns via breastfeeding [1,3,9,10,35,36].
TBBPA has been shown to be a ligand for several hor-
one receptors in vitro. TBBPA is a T4 competitor in the
TR-binding assay [19,20] and binds to the rat thyroid
ormone receptor with high afﬁnity [25]. TBBPA was also
eported  to bind to human transthyretin [28]. Both TBBPA
nd  TBBPA-sulfate have been shown to be human peroxi-
ome  proliferator-activated receptor  [31,32]. In studies
sing the estrogen-dependent rat pituitary tumor cell line
tT/E-2,  TBBPA enhanced proliferation but to a lower
xtent than its non-brominated analog, bisphenol A [25].
BBPA  binds to the estrogen receptor, but to a lower degree
han  bisphenol A [33]. TBBPA was an estrogen receptor sub-
ype  alpha (ER) agonist and a progesterone receptor (PR)
ntagonist in transfected yeast. TBBPA and two metabolites
2,6-dibromo-4-[2-hydroxypropane-2-yl]-phenol and 2,6-
ibromo-4-[2-methoxypropane-2-yl]-phenol) have been
hown  to have estrogenic activity in MCF-7 cells [26,33,39].
BBPA has been shown to be an inhibitor of estradiol sul-
ation  in vitro [19]. Recent crystallographic studies show
hat  it can be bound with high afﬁnity to the estrogen sul-
otransferase SULT1E1 [16].
TBBPA has an LD50 of greater than 5 g/kg when adminis-
ered as a single dose by gavage to rats [21]. Intraperitoneal
dministration of TBBPA has been shown to cause hep-
totoxicity and heme metabolism disturbances [37,38],
henomena that may  relate to the formation of free
adicals in vivo [11]. In repeat-dose subacute and one-
eneration reproductive studies, TBBPA exposures resulted
n  decreased thyroxine levels and other endocrine effects
40].  Hakk et al. [18] demonstrated that, at a dose of
 mg/kg, TBBPA is readily absorbed from the gastroin-
estinal tract of male Sprague Dawley (SD) rats where
t  undergoes biotransformation to o-glucuronide and o-
ulfate  conjugates followed by biliary elimination. TBBPA
as  eliminated in the feces as parent compound demon-
trating intestinal deconjugation. Similarly, at a 300 mg/kg
ose  of TBBPA to male SD rats, TBBPA was rapidly
bsorbed with a plasma Cmax of 103 mol/L reached within
 h; TBBPA-sulfate was the major metabolite detected in
lasma  along with TBBPA-glucuronide [34]. Kang et al.
24]  reported plasma Cmax values of 23, 34, and 57 mol/L
or  oral doses of 200, 500, and 1000 mg/kg TBBPA (Tmax
ccurred at 4.2–5 h), respectively for male SD rats; metabo-
ites  were not described. Kuester et al. [27] demonstrated
hat at a 20 mg/kg dose of TBBPA in male Fischer-344 (F-
44)  rats, the systemic bioavailability of the compound
as low (1.6%). The bioavailability of TBBPA in humans is
nknown,  although it is expected to be low. TBBPA was
bsorbed from the gut of healthy human volunteers receiv-
ng  a single oral dose of 0.1 mg/kg but TBBPA was below
he  limit of detection in all blood samples. However, a
lucuronide conjugate of TBBPA was present in samples
ollected at all of the time points up to 72 h, with peak
oncentrations detected between 2 and 6 h and traces ofFig. 1. Chemical structure of TBBPA.
TBBPA-glucuronide were detected in urine [34]. TBBPA was
detected  at low levels (<1–3.4 pmol/g lipid) in serum of
computer workers and workers in an electronics disman-
tling  plant [17,22]. TBBPA was  metabolized by human liver
subcellular fractions in a similar fashion to those of rats
[41].
Ongoing analyses of data from TBBPA chronic expo-
sure studies has demonstrated that TBBPA induced
highly malignant uterine tumors in female Wistar Han
[Crl:WI(Han)] rats in a dose-dependent manner. Male
Crl:WI(Han) rats did not develop a signiﬁcant tumor bur-
den  whereas administration of TBBPA resulted in increased
incidences of nonneoplastic lesions of the liver and kid-
ney  in male B6C3F1 mice and in the forestomach of male
and  female mice [30]. However, no disposition, metabolism
or  kinetics data are available for the female Crl:WI(Han)
rat. Therefore, studies were conducted to characterize the
disposition of TBBPA in female Crl:WI(Han) rats following
single or repeated oral or intravenous administration. The
toxicokinetic proﬁle of TBBPA in plasma after a 250 mg/kg
dose  was  also investigated, as this dose was the lowest dose
found  to be associated with tumor formation in the NTP
2-year  bioassay [30].
2.  Materials and methods
2.1.  Chemicals
[14C]-Radiolabeled TBBPA (uniform ring-labeled; Fig. 1),
previously described by Kuester et al. [27] was  gener-
ously provided by I. Glenn Sipes at the University of
Arizona (Tucson, AZ) for use in the present study. Reversed-
phase HPLC fractionation (described below) was used to
acquire  a radiochemical purity of >98% (speciﬁc activ-
ity  = 90.3 mCi/mmol). [14C]-TBBPA was  reconstituted in
dimethyl sulfoxide. Chemical purity was determined to
be  >98% as compared to a TBBPA reference standard
(Sigma–Aldrich; St. Louis, MO). Scintillation cocktails were
obtained from MP  Biomedicals (Ecolume; Santa Ana, CA)
or  Perkin-Elmer (Ultima-Flo M & PermaFluor E+; Torrance,
CA).  Cremophore EL®, dimethylsulfoxide, -glucuronidase
(EC 3.2.1.31, Type B-10), ammonium acetate, d-saccharic
acid 1,4-lactone, and aryl sulfatase were purchased from
Sigma–Aldrich. All other reagents used in these studies
were high performance liquid chromatography (HPLC) or
analytical  grade.
ology R216 G.A. Knudsen et al. / Toxic
2.2. Animal model
Female  Crl:WI(Han) rats (11 weeks, ∼200 g at time
of dosing; Charles River, Raleigh NC) were used in these
studies. Animals were maintained in an AAALAC-approved
animal care facility for a minimum of 7 days in plastic
shoebox cages prior to dosing. Animals were housed indi-
vidually  in plastic metabolism cages for separate collection
of  urine and feces. Food (NIH #31) and water were provided
for  ad libitum consumption. All procedures were approved
by  the NIEHS Institutional Care and Use committee.
2.3. Dosing
Animals were administered a single dose of TBBPA
by gavage or by intravenous (IV) bolus through an
indwelling catheter. Dosing solutions were formulated to
administer  ∼50 Ci/kg/rat and contained amounts of non-
radiolabeled TBBPA for delivery of doses up to 1000 mg/kg.
Oral  doses were: 25, 250 (4 mL/kg) or 1000 mg/kg (8 mL/kg)
and  the IV dose was administered at a dose level of
25  mg/kg (1 mL/kg). Dosing vehicle was ethanol, water, and
an  emulsifying agent (Cremophore EL®) in a 1:3:1 ratio.
Dosing solutions contained 2% or less DMSO.
2.4. Sample collections
Following  administration of the compound
(N = 3–6/treatment group) excreta and cage rinses were
collected at 6, 12, 24, 48, and 72 h. Animals were euth-
anized by CO2 asphyxiation. Tissues (adipose, adrenals,
brain, heart, kidneys, large intestine & contents, liver,
lung, muscle, pancreas, ovaries, skin, small intestine &
contents, spleen, stomach & contents, thymus, thyroid,
urinary bladder, and uterus) were collected at necropsy
and stored at −80 ◦C until analysis. Blood samples were
collected via cardiac puncture at the time of death. Ani-
mals  used in kinetic studies (250 mg/kg oral and 25 mg/kg
IV)  contained an indwelling jugular vein cannula from
which blood (∼150 L) was obtained using heparinized
syringes at 7.5 min, 15 min, 30 min, 1 h, 3 h, 6 h, 12 h, and
24  h post-dose. Withdrawn blood volumes were replaced
with  equal amounts of saline. One group of rats with
an  indwelling common bile-duct cannula was  used to
determine biliary elimination of TBBPA metabolites fol-
lowing  a 250 mg/kg dose. Animals were surgically altered
by  the vendor (Charles River) and were fully recovered
from anesthesia before delivery (approx. 24 h before
dosing). Bile was collected continuously and analyzed at
1  h intervals up to 6 h post-dose. Samples were placed in
labeled  pre-weighed vials after all collections and main-
tained at −80 ◦C until analyses. Plasma was isolated from
heparinized blood by centrifugation (5 min  at 3000 RPM).
Bile  samples (∼100 L) were diluted with 1 mL  water prior
to  analyses. Total mass of incompletely necropsied tissues
were  calculated based on percentages of ﬁnal body weight
(adipose: 11%, muscle: 50%, skin: 16%) using previously
published values [6]. All other tissues were completely
collected and weighed gravimetrically.eports 1 (2014) 214–223
2.5. Analytical methods
Samples  were analyzed in parallel for quantitative and
qualitative analyses. Quantitative analyses of total [14C]-
radioactivity content was determined using a Beckman
Coulter (Brea, CA) LS6500 Liquid Scintillation Counter
(LSC). Total [14C]-radioactivity content of bile (100 L),
plasma (10 L), urine (10–100 L) and cage rinses (1 mL)
was  assayed in triplicate with the LSC. Fecal samples were
air  dried in a fume hood, weighed and ground to a powder
using a mortar and pestle. Triplicate aliquots of feces and
tissues  (∼25 mg)  were weighed and [14C]-radioactivity was
quantiﬁed following combustion in a Packard 307 Biologi-
cal  Sample Oxidizer by LSC analysis.
To determine the nature of phase II metabolites of
TBBPA in bile, samples were incubated at 55 ◦C for
60 min  with -glucuronidase (5000 U/mL) or aryl-sulfatase
(11 U/mL) as described by Andersen et al. [2]. Bile incu-
bated with buffer (200 M ammonium acetate in water, pH
5.0)  was incubated under identical conditions and served as
controls.  Reactions were terminated by rapidly cooling the
samples  to −20 ◦C followed by HPLC-radiometric analyses.
For  plasma toxicokinetic analyses, TBBPA was  quanti-
ﬁed by UV/Vis absorbance at 210 nm and radiochemical
detection following HPLC separation. [14C]-TBBPA was
puriﬁed using an HPLC system composed of a Waters
1525 binary HPLC pump, Phenomenex Luna 5  C18(2)
250 × 4.6 mm column (Phenomenex, Torrance CA), and
a  Waters 2487 dual  absorbance detector with an in-
line  IN/US -RAM model 3 Flow Scintillation Analyzer
(LabLogic, Inc., Brandon FL). The HPLC system used for
analysis of biological samples was  composed of a Waters
2695  Separations Module, Agilent Eclipse Plus C18 column
(3.5  m,  4.6 mm × 150 mm),  and a Waters 996 Photodiode
Array with an in-line Radiomatic 500TR Flow Scintillation
Analyzer. Mobile phases consisted of 0.1% triﬂuoroacetic
acid in water (mobile phase A) and 0.1% triﬂuoroacetic acid
in  acetonitrile (mobile phase B). Sample separations were
performed using a gradient; initial conditions (60% A) were
maintained for 5 min; A was  then reduced to 10% over 2 min
then  to 0% A over 13 min. The column was  returned to ini-
tial  conditions and allowed to equilibrate for 5 min  before
re-use. Flow rates were 1 ml/min. Instrument control and
analysis  software were Empower Pro (Waters Corp.) and
FLO-ONE  for Windows (Packard Instruments Co., Inc.; v.
3.6).  TBBPA was quantiﬁed based on a 5-point calibration
curve.
Biliary metabolites were further characterized by LC/MS
analyses. The LC/MS consisted of an Agilent 1100 HPLC
(Agilent Technologies, Santa Clara CA) and a ThermoFinni-
gan LCQ AdvantageMax mass spectrometer (Thermo
Scientiﬁc, Waltham MA)  equipped with an ESI source. Trap
conditions were similar to those described by Kang et al.
[23].  Conditions were: sheath gas = N2 at 20 L/min, cap-
illary temperature = 275 ◦C, spray voltage = 5 kV, capillary
voltage = −33 V, tube lens offset = −30 V. The collision gas
was  Helium and ions were isolated over a mass window of
5  Da for tandem mass spectrometric studies. HPLC mobile
phases consisted of 100% acetonitrile (A) and 100% water
(B)  using isocratic conditions (A:B, 70:30) with a ﬂow rate
of  200 L/min. Bile samples were fractionated prior to MS
G.A. Knudsen et al. / Toxicology Reports 1 (2014) 214–223 217
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nalysis using the Waters HPLC system and fractions col-
ected  between 1–3 min  and 7–9 min  were infused into the
C/MS  using a syringe pump. Following conﬁrmation of the
ass  of TBBPA (543 Da), full mass spectrometry (MS) scans
ere  performed followed by manual selection of the most
bundant ions for isolation and fragmentation.
.6. Pharmacokinetic modeling
Free  TBBPA in plasma collected from individual
nimals at each time point described above (deter-
ined by UV/radiometric-HPLC) was used to construct
 time–concentration data table for each animal. These
ata were ﬁt to established pharmacokinetic models using
he  Phoenix WinNonlin (Certara USA, Inc.; St. Louis, MO)
oftware package. Time–concentration data from animals
dministered TBBPA intravenously were ﬁt to a one-
ompartment model with bolus input and ﬁrst order
utput. Time–concentration data from animals adminis-
ered TBBPA by gavage were ﬁt to a one-compartment
odel with ﬁrst order input and output or a two-
ompartment model with ﬁrst order input and output.
inal distribution/elimination phases were assessed by
on-compartmental analysis based on observed deviations
rom  concentrations predicted by compartmental analy-
es.  Goodness of ﬁt was assessed by comparing the sum
f  squared residuals.
.  Results
.1. Distribution and elimination studies
The primary route of elimination of radioactivity was
n  feces following oral administration of [14C]-TBBPA;
ose recoveries in 72 h were 95.7 ± 3.5%, 94.3 ± 3.6% and
8.8  ± 2.2%, for the 25, 250, and 1000 mg/kg dose, respec-
ively (Fig. 2). Animals administered 1000 mg/kg of TBBPA
howed a clear delay in rates of fecal elimination through
4  h. Urine contained from 0.2–2% of dose. Less than 0.1%
f  the administered [14C]-radioactivity was detected in tis-
ues  collected at 72 h following oral doses. In addition, four
nimals  were administered TBBPA (250 mg/kg) for 5 days
o  determine the effects of repeated exposure on elim-
nation and distribution. Four doses of non-radiolabeled
BBPA were followed by a single dose of [14C]-labeled
BBPA (50 Ci/kg) and animals were euthanized 24 h after Ta
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the ﬁnal dose. Recoveries were similar to those found fol-
lowing  a single dose, with 84 ± 8% of the terminal dose
recovered from feces (76 ± 22% was recovered by 24 h in
single-dose studies). Less than 1% of the dose was  recovered
in  urine and tissue retention was similarly minimal.
The amount of administered [14C]-radioactivity
in selected tissues was estimated at 1, 3, 6, 24, and
72 h following oral administration of [14C]-TBBPA
(250 mg/kg, 50 Ci/kg). The vast majority of recov-
ered [14C]-radioactivity was found in the gastrointestinal
tract contents at 1, 3, and 6 h (Table 1). Radioactivity in
blood  accounted for 1–8% of the dose at these early time
points. Tissues contained little radioactivity at 24 h (<2%),
with  the majority of the unrecovered radioactivity present
in  the large intestine contents at this time point. Small
but  measurable amounts of TBBPA-derived radioactivity
remained in the liver, muscle, skin, and small intestine,
as well as the small and large intestinal contents at 72 h
following oral doses of 25, 250, or 1000 mg/kg (Table 2).
Adrenals, brain, heart, ovaries, spleen, thymus, thyroid,
urinary bladder, and uterus retained less that 0.01% of
administered doses.
A  set of animals received TBBPA by IV administra-
tion to enhance interpretation of oral absorption data. At
6  h post-dosing (25 mg/kg, 50 Ci/kg) [14C]-radioactivity
was present in the large intestine (3.2 ± 3%), small intes-
tine  (3.2 ± 3.1%), liver (1.8 ± 0.6%), and adipose (1 ± 0.8%)
tissues; all other tissues retained less than 1% of the admin-
istered  dose at 6 h post-dose. Approx. 10% and 1% of the
administered radioactivity was eliminated in the feces
and  urine, respectively, within 6 h. The remainder of the
dose  was recovered in the contents of the small and large
intestines (approx. 15% and 61% at 6 h post dose, respec-
tively). Conversely, animals administered 250 mg/kg by
gavage  eliminated 1–12% of the administered radioactiv-
ity into bile in 6 h, while 36% remained in the stomach
and 9% was recovered from small intestine contents (1% in
large  intestine contents); approx. 8% of the dose was  found
in  the blood, consistent with plasma toxicokinetic studies
described below. These data support the conclusion that
TBBPA  is cleared from the systemic compartment via bile
for  fecal elimination.
Two  major [14C]-radiolabeled metabolite peaks and a
small  amount of parent TBBPA were detected in bile of
the  rats receiving 250 mg/kg by gavage (Rt = 2 and 8 min
respectively; Rt for [14C]-TBBPA = 14.5 min; Fig. 3). Incuba-
tion  with -glucuronidase resulted in increased detection
of  parent compound with stoichiometric reductions of
metabolite 2 (M2). Incubation with sulfatase resulted in
Table 2
Disposition of [14C]-radioactivity following oral administration of TBBPA: 25, 250
25 mg/kg, 72 h (N = 4) 250 mg
% dose (nmol-eq/g tissue) % dose 
Mean  ± S.D. (Mean ± S.D.) Mean ±
Large intestine contents 0.02 ± 0.03 (0.5 ± 0.6) 0.02 ±
Small  intestine contents <0.01 (0.07 ± 0.08) 0.01 ±
Liver  0.01 ± 0.002 (0.1 ± 0.01) 0.02 ±
Small  intestine <0.01 (0.05 ± 0.04) <0.01 
Muscle  0.02 ± 0.03 (0.02 ± 0.02) <0.01 
Skin  0.01 ± 0.01 (0.02 ± 0.02) <0.01 Fig. 3. Representative HPLC-radiometric chromatograms of TBBPA
metabolites in bile after oral administration of [14C]-TBBPA (250 mg/kg,
PO).
the disappearance of metabolite 1 (M1) and a reduction in
the  recovery of M2.  Parent peak area increased with both
enzymatic treatments. Residual -glucuronidase activity in
the  sulfatase reaction media likely accounts for the loss of
M2.
M1  and M2  were isolated from bile using the HPLC
method described above and were subjected to electro-
spray mass spectral analyses. Infusion of the M1 fraction
(Rt  = 2 min) showed a major ion with m/z = 625 (Fig. 4, panel
A).  Collision induced fragmentation of this ion resulted the
loss  of 82 Da (consistent with the mass of a sulfuryl group)
and  formation a daughter ion with m/z = 543. Infusion of
the  M2  fraction (Rt = 8 min) resulted in a major ion with
m/z  = 832 (Fig. 4, panel B). Collision induced fragmentation
of this ion resulted in the loss of 114 Da (triﬂuouracetic acid
adduct)  and formation a product ion with m/z = 718. This
ion  was further fragmented resulting in the loss of 175 Da
(glucuronic acid) with a resulting ion with m/z = 543. As
such,  M1 has been identiﬁed as TBBPA-sulfate and M2  as
TBBPA-glucuronide.3.2.  Plasma toxicokinetic studies
Toxicokinetic proﬁles for TBBPA in plasma following
oral or IV administrations were estimated based on free
, or 1000 mg/kg at 72 h.
/kg, 72 h (N = 4) 1000 mg/kg, 72 h (N = 4)
(nmol-eq/g tissue) % dose (nmol-eq/g tissue)
 S.D. (Mean ± S.D.) Mean ± S.D. (Mean ± S.D.)
 0.01 (21 ± 32) 0.4 ± 0.3 (241 ± 169)
 0.01 (3 ± 3) 0.08 ± 0.06 (63 ± 50)
 0.01 (2 ± 1) 0.04 ± 0.01 (17 ± 5)
(1 ± 1) 0.01 ± 0.01 (14 ± 6)
(0.2 ± 0.2) 0.03 ± 0.02 (1 ± 0.8)
(3 ± 5) 0.01 ± 0.01 (1 ± 0.7)
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Fig. 4. Electrospray mass spectrum of ([M−H]− ion) of A: TBBPA biliary metabolite peak 1 (TBBPA-sulfate); B: collision induced fragmentation of m/z 625
g  TBBPA-
a
T
t
o
1ives  a loss of 80 amu); C: TBBPA biliary metabolite peak 2 (TFA-adducted
 loss of 114 and 176 amu, respectively).BBPA detected in plasma (Fig. 5, panel A). Oral adminis-
ration of TBBPA (250 mg/kg) resulted in a rapid absorption
f  compound, with a mean Cmax of 5.4 mol/L occurring at
27  min  post-dose and the decline in plasma concentrationglucuronide); D: collision induced fragmentation of m/z 832 & 719 givesconsistent with a one-compartment model. The absorp-
tion  and elimination half-lives were ∼54 and 155 min,
respectively. When TBBPA was  given by IV administration
(25 mg/kg), plasma concentrations rapidly decreased,
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Fig. 5. Time–concentration proﬁles of TBBPA in plasma following A: oral administration, 5 min-24 h (250 mg/kg; N = 3); B: IV administration, 5 min-6 h
s quanti(25  mg/kg; N = 4). Regression lines show model-predicted data. TBBPA wa
2).
with ∼2% of the administered radioactivity remaining at
6  h post dose (Fig. 5, panel B). The time–concentration
proﬁle for free TBBPA in plasma following IV admin-
istration of [14C]-TBBPA was largely consistent with a
two-compartment model (distribution half-life = 2 min;
terminal half-life = 22 min). However, the observedﬁed by UV-detection at 210 nm following separation by HPLC (see Section
goodness of ﬁt at late time-points was sub-optimal,
especially at the terminal time-points, resulting in over-
estimation of clearance rates for TBBPA from the central
compartment. To better estimate clearance, data were
subjected to non-compartmental analyses whereupon the
terminal  half-life following oral administration of TBBPA
G.A. Knudsen et al. / Toxicology Re
Table 3
TBPA  bioavailability parameters in female Crl:WI(Han) rats.
Dose AUC F
(nmol)  (min*nmol/mL) (%)
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dIV (25 mg/kg) 8580 4286
4.8%Oral (250 mg/kg) 72,323 1729
as ∼290 min; following IV, 133 min. Taken together, these
esults  show there is less than 5% systematic bioavailability
or TBBPA in female Crl:WI(Han) rats (Table 3).
.  Discussion
Female Crl:WI(Han) rats exhibited similar ADME/TK
haracteristics as those described for male F-344 [27] and
ale  SD rats [18,24,34]. TBBPA appeared to have low sys-
emic  bioavailability due to a signiﬁcant ﬁrst pass effect in
he  liver, with biliary elimination leading to fecal excretion
t  all does examined and after repeated administrations
f 250 mg/kg. Plasma levels of TBBPA described here were
p  to 3 orders of magnitude higher than those observed
n  serum from occupationally-exposed humans. Neverthe-
ess,  these data may  be useful in describing the upper
ounds of exposure for conservative risk assessments of
BBPA  exposures.
The  results presented here, along with data from other
tudies, indicate that TBBPA is absorbed from the gas-
rointestinal tract following oral administration to female
rl:WI(Han) rats. Signiﬁcant ﬁrst pass metabolism was
ikely  and rapid elimination of an IV-administered dose
nto  the gut contents and feces supported this conclusion.
ow levels of parent compound did persist in the free frac-
ion  of plasma for up to 24 h, indicating a possible route
or  low level on-going exposure to tissues such as the
terus. Entero-hepatic cycling following deconjugation by
ut  microﬂora [5] and/or action by tissue glucuronidases
4] may  play a role in preserving this persistent low level
f  TBBPA. Additionally, individuals deﬁcient in speciﬁc con-
ugation  capacities, esp. fasting and frail adults [14,29] as
ell  as infants and neonates [15] may  be exposed to higher
ystemic levels, especially at high doses of TBBPA. Addition-
lly,  as TBBPA is being used more extensively as an additive
FR  in consumer products, it is expected that higher con-
inuous  exposures will be experienced by more diverse and
ensitive  populations.
Low  but detectable amounts of TBBPA persisting in
lood at the 12 and 24 h time points could not be
ccounted for in the simple one-compartment model
nd inter-individual variation (Crl:WI[Han] rats are an
utbred  strain) precluded meaningful model ﬁt to a 2-
ompartment oral model. This persistence of compound
n plasma may  be due, at least in part, to entero-hepatic
irculation of TBBPA. Notably, biliary elimination of [14C]-
adioactivity was appreciably lower at 250 mg/kg in fed
emale  Crl:WI(Han) rats, with 12% or less of the dose
liminated in bile in 6 h following 250 mg/kg oral adminis-
ration of TBBPA, as compared with ∼50% of dose recovered
n  bile in 2 h following a 20 mg/kg dose administration
o fasted F-344 male rats [27]. Saturation of absorption,
elayed gastric emptying, or binding to food particles mayports 1 (2014) 214–223 221
have  contributed to the apparent increase in retention
of compound in the stomach contents. Tissue distribu-
tion was minimal, with appreciable (>1% of dose) being
recovered in GI tract contents rather than within tissues
at  all time-points, further supporting a major role for
hepatic detoxiﬁcation and elimination of TBBPA in vivo
even  after repeated administrations. Evidence from short-
term  (1–6 h) exposure studies suggest biliary elimination
of TBBPA-derived material is slower in non-fasted female
Crl:WI(Han) rats than has been previously reported using
other  strains. However, these data indicate that TBBPA
has  a similar ADME-TK proﬁle in female Crl:WI(Han) rats
as  that previously reported for male SD or F-344 rats
[18,27].
Doses selected for the studies were based on those cal-
culated as a function of maximum tolerated dose rather
than  as a function of occupational exposures and were anal-
ogous  to those used in the National Toxicology Program
2-year cancer bioassay [30]. There was  no evidence of pref-
erential  distribution or retention of TBBPA in uterus leading
to  the conclusion that the dispositional fate of TBBPA
did not appear to have a direct linkage to TBBPA-dose
dependent uterine carcinogenicities. To that end, uterine
carcinogenesis seen in female Crl:WI(Han) rats following
TBBPA exposure may  be due to indirect endocrine dis-
ruption; there is emerging evidence that TBBPA disrupts
estrogen metabolism by competing for access to tissue-
speciﬁc sulfotransferases, e.g. SULT1E1 [16]. Alterations
in estrogen signaling pathways by chronic exposure to
high  levels of TBBPA may  contribute to the cellular events
necessary for the uterine neoplasia demonstrated in the
2-year  cancer bioassay of TBBPA [30]. Long term expo-
sures may  be needed before treatment-related effects are
manifested. It is critical to note that the uterine carcino-
genesis see in female Crl:WI(Han) rats is due to indirect
endocrine disruption, as shown in high dose animals stud-
ies  as well as in vitro data, with unknown relevance to
humans exposed at environmental levels via plausible
routes of exposure. Additional studies are being conducted
to  delineate endocrine, cellular, proteomic and/or genomic
changes associated with TBBPA-dependent carcinogenicity
in rodents.
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Appendix A. Supplementary data
Supplementary data associated with this article can be
found,  in the online version, at doi:10.1016/j.toxrep.2014.
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